Mode
Text Size
Log in / Sign up
N/A N=15 Other

Follow-Up Study Validating a Blended Technique to Identify the Proximal Humerus Intraosseous Vascular Access Site

Intraosseous Vascular Access · Vascular Access

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Proximal Humerus Intraosseous (IO) Insertion Site Placement Total Score — 6.0; 1.2; 4.8 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Intraosseous Vascular Access (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Vidacare Corporation
Primary completion
May 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Proximal Humerus Intraosseous (IO) Insertion Site Placement Total Score
6.0; 1.2; 4.8
PRIMARY
Time to Intraosseous Catheter Placement
178.0
PRIMARY
Level of Confidence Score Pre-intraosseous Insertion
3.22
PRIMARY
Level of Confidence Score Post-intraosseous Insertion
4.1
PRIMARY
Ease of Use Score Pre-intraosseous Insertion
4.11
PRIMARY
Ease of Use Score Post-intraosseous Insertion
4.5
SECONDARY
Intraosseous Infusion Flow Rates
SECONDARY
Time in Seconds for Fluid Delivery From the Proximal Humerus to the Heart
2.44
SECONDARY
Success Rate of Obtaining Laboratory Results for Both Intraosseous and Peripheral Venous Specimens
4

Summary

A Follow-up Study Validating a Blended Technique for Identifying the Proximal Humerus Intraosseous Vascular Access Insertion Site

Eligibility Criteria

Inclusion Criteria Device Operators:

  • Currently licensed/certified Emergency Medicine Technicians, paramedic, or nurse
  • Have had no formal training on use of the proximal humerus IO insertion site
  • Demonstrate proper use of the device and technique during training portion and obtain approval from the device trainer to participate

Exclusion Criteria for Device Operators: None

Inclusion Criteria Healthy Subjects:

  • Age 21 years or older
  • Have no amputation of the upper extremities
  • Able to lay flat on a table for up to 2 hours
  • Self-reported as healthy, as confirmed by the PI

Exclusion Criteria Health Subjects:

  • Have an active infection in the body
  • Imprisoned
  • Pregnant
  • Cognitively impaired
  • Fracture in humerus, or significant trauma to the site
  • Excessive tissue and/or absence of adequate anatomical landmarks in humerus
  • Infection in target area
  • Humeral IO insertion in past 48 hours, prosthetic limb or joint or other significant orthopedic procedure in humerus
  • Current use of anti-coagulants
  • Current cardiac condition requiring pacemaker or anti-arrhythmic drugs
  • Prior adverse reaction to lidocaine
  • Volunteers with any of the following characteristics may be excluded from the infusion pathway evaluation involving administration of contrast dye at the discretion of the PI:
  • Prior adverse reaction to contrast dye
  • Allergy to any food or drug
  • History of impaired renal function
  • History of impaired hepatic function
  • History of cardiac disease
  • History of pheochromocytoma
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01866501). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search